Stock Track | MoonLake Immunotherapeutics Soars 43.58% in Pre-Market on FDA Feedback and Investor Day Announcement

Stock Track01-08

MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.

The company announced a positive outcome from a Type B meeting with the U.S. FDA, confirming it can establish SEE without additional trials. Additionally, MoonLake revealed plans to host an Investor Day on February 23, 2026, to discuss FDA feedback, share new clinical data, and outline its 2026 catalyst calendar.

Further boosting investor confidence, MoonLake disclosed plans to submit a Biologics License Application (BLA) for SLK in HS in the second half of 2026, signaling progress in its pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116502352?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116502352","market":"nz","top_or_hot":-1,"title":"Stock Track | MoonLake Immunotherapeutics Soars 43.58% in Pre-Market on FDA Feedback and Investor Day Announcement","media":"Stock Track","content":"<p>MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.</p><p>The company announced a positive outcome from a Type B meeting with the U.S. FDA, confirming it can establish SEE without additional trials. Additionally, MoonLake revealed plans to host an Investor Day on February 23, 2026, to discuss FDA feedback, share new clinical data, and outline its 2026 catalyst calendar.</p><p>Further boosting investor confidence, MoonLake disclosed plans to submit a Biologics License Application (BLA) for SLK in HS in the second half of 2026, signaling progress in its pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MoonLake Immunotherapeutics Soars 43.58% in Pre-Market on FDA Feedback and Investor Day Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MoonLake Immunotherapeutics Soars 43.58% in Pre-Market on FDA Feedback and Investor Day Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-08 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.</p><p>The company announced a positive outcome from a Type B meeting with the U.S. FDA, confirming it can establish SEE without additional trials. Additionally, MoonLake revealed plans to host an Investor Day on February 23, 2026, to discuss FDA feedback, share new clinical data, and outline its 2026 catalyst calendar.</p><p>Further boosting investor confidence, MoonLake disclosed plans to submit a Biologics License Application (BLA) for SLK in HS in the second half of 2026, signaling progress in its pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MLTX","symbol_name":"MoonLake Immunotherapeutics","start_time":0,"source_url":"","article_id":"1116502352","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116502352","pubTimestamp":1767878080,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.The company announced a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MLTX":"MoonLake Immunotherapeutics"},"translate_title":"个股追踪|FDA反馈及投资者日公告MoonLake Immunotherapeutics盘前大涨43.58%","themeId":"33791b051befbfd8525af904615f530c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":1},"content_text":"MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.The company announced a positive outcome from a Type B meeting with the U.S. FDA, confirming it can establish SEE without additional trials. Additionally, MoonLake revealed plans to host an Investor Day on February 23, 2026, to discuss FDA feedback, share new clinical data, and outline its 2026 catalyst calendar.Further boosting investor confidence, MoonLake disclosed plans to submit a Biologics License Application (BLA) for SLK in HS in the second half of 2026, signaling progress in its pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116502352","isCrawlerRequest":true}